Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | PYGB | P11216 | 7/20 | 0.33 |
| ▸ | PYGL | P06737 | 3/20 | 0.32 |
| ▸ | PYGM | P11217 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31207232 | 0.84 | GBA1 (0.36) | GBA1GAAMEN1KMT2APYGB | |
| SCHEMBL29555015 | 0.84 | GBA1 (0.36) | GBA1GAAMEN1KMT2APYGB | |
| SCHEMBL23722750 | 0.84 | PYGB (0.40) | GBA1GAAMEN1KMT2APYGB | |
| SCHEMBL9504070 | 0.84 | PYGB (0.40) | GBA1GAAMEN1KMT2APYGB | |
| SCHEMBL29454922 | 0.80 | GAA (0.38) | GBA1GAAMEN1KMT2APYGB | |
| SCHEMBL7623220 | 0.79 | SPHK2 (0.36) | GBA1GAA | |
| SCHEMBL31513810 | 0.76 | GBA1 (0.41) | GBA1GAAPYGBPYGLPYGM | |
| SCHEMBL31347458 | 0.75 | GBA1 (0.43) | GBA1GAAPYGBPYGLPYGM | |
| SCHEMBL30177611 | 0.73 | GBA1 (0.42) | GBA1GAAPYGBPYGLPYGM | |
| SCHEMBL30549234 | 0.73 | GBA1 (0.42) | GBA1GAAPYGBPYGLPYGM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8513394-B2 | Saccharide fluorescent substrates, preparation method and uses thereof | COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) | 2013-08-20 | — | — | US | disclosed |
| EP-1904847-B1 | SACCHARIDE FLUORESCENT SUBSTRATES, PREPARATION METHOD AND USES THEREOF | COMMISSARIAT ENERGIE ATOMIQUE (FR) | 2009-09-16 | — | — | EP | disclosed |
| US-20080299044-A1 | Saccharide Fluorescent Substrates, Preparation Method and Uses Thereof | COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) | 2008-12-04 | — | — | US | disclosed |
| EP-1904847-A2 | SACCHARIDE FLUORESCENT SUBSTRATES, PREPARATION METHOD AND USES THEREOF | COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) | 2008-04-02 | — | — | EP | disclosed |
| WO-2007010145-A2 | SACCHARIDE FLUORESCENT SUBSTRATES, PREPARATION METHOD AND USES THEREOF | COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) | 2007-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080299044-A1 | Saccharide Fluorescent Substrates, Preparation Method and Uses Thereof | FUCA1, MPI, ENGASE | GBA1 54/4885GAA 34/4885MEN1 659/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.